Key Highlights

  • Alterola Biotech shares are trading 21.88% higher on Wednesday, October 28, 2026, at a price below one cent.
  • The last quote the company's page showed was $0.0002 on September 9, 2026, with a 52-week range of $0.0002 to $0.0065.
  • Market capitalisation was about $296,000 on 1.48 billion shares outstanding at that quote.
  • Alterola signed settlement and unwind agreements with Protagenic Therapeutics on February 17, 2026, and recovered all assets.
  • Net loss over the trailing twelve months was about $2.78 million, with no reported revenue.

Alterola Penny Stock Move: Why Are Shares Trading 22% Higher Without News?

Alterola Biotech (OTC:ABTI) shares are trading 21.88% higher on Wednesday, October 28, 2026, at a price below one cent, placing the stock among the most active penny stocks of the session. No dated company release accompanied the move, and none of the filings or announcements examined points to a catalyst for today's activity.

The last quote on the company's public page was $0.0002 on September 9, 2026, on volume of only 8,000 shares, so a double-digit percentage swing reflects a very small change in absolute terms. At sub-cent levels a single tick can register as a large percentage move.

Alterola Business: What Does the Cannabinoid Drug Developer Own?

Alterola Biotech is a United Kingdom based pharmaceutical company, run from Birkenhead, that develops medicines from cannabinoid and cannabinoid-like molecules, including human and animal health products, food-grade ingredients and drug delivery formulations. The chief executive is David Hitchcock, and the fiscal year runs from April to March.

The company describes its asset base as cannabinoid assets, modified stilbenoid assets and Kv7.2/7.3 voltage-gated potassium channel modulators. Its directors say they are exploring funding options to develop those assets or to monetise them. The company reports no revenue.

Protagenic Share Exchange Unwound: How Did the Dispute Resolve?

On May 15, 2025, Alterola agreed a share exchange with Protagenic Therapeutics (NASDAQ:PTIX), a transaction involving its subsidiary Phytanix Bio. On August 13, 2025, Protagenic filed a current report that raised what Alterola's directors called serious concerns, and on August 15, 2025, Alterola updated shareholders and filed a Form 15 notice that moved it to non-reporting status.

The dispute ended in February 2026. Settlement and unwind agreements were signed on February 17, 2026, and the company announced on February 24, 2026 that the original transaction had been reversed and all assets recovered. That leaves Alterola as a standalone owner of its drug assets with limited public disclosure obligations.

Financial Position: How Thin Is the Balance Sheet Behind the Quote?

The most recent balance sheet data available covers the period ended September 30, 2024. Cash was about $0.08 million against total debt of about $2.35 million and total liabilities of about $3.62 million, leaving shareholders' equity at negative $2.25 million. Shares outstanding were roughly 1.47 billion then and 1.48 billion at the latest quote.

Trailing net loss was about $2.78 million. At $0.0002, market capitalisation was about $296,000, and the 52-week range of $0.0002 to $0.0065 shows how far the price has compressed.

What to Watch Next: Funding Plans and Any First Disclosure Since the Unwind

Because Alterola stopped filing periodic reports in August 2025, investors have few scheduled events to follow. The items that matter are any announcement on funding or monetisation of the cannabinoid and Kv7 assets, the next update after the February 24, 2026 unwind, and whether volume stays elevated after today's move.